Enhance your practice with CME and tools that focus on the management of neurological conditions.
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
Orlando, Florida
Proactive Pregnancy Planning and Reproductive Care in MS
Riley Bove, MD, MMSc
Addressing Social and Systemic Barriers in Schizophrenia
Shelina Ramnarine, PhD
Margaret Emerson, DNP, APRN, PMHNP-BC
The Social Brain in Schizophrenia
Michael Green, PhD
Depression as a Signal of MS Progression
Target Locked in gMG: Why T2T Matters
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
11:45 AM - 12:45 PM ET
Turning Flares Into Function: Flag Uncontrolled Disease
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
The 2-Point Signal: Apply ≥2-Point Rule
Advancing Pediatric MS Care: Insights from AAN 2026
Elizabeth Wilson, MD
Updates in MS Care: Key Topics at AAN 2026
Aaron Miller, MD
Emerging Serum microRNAs as Early Signals in MS
Family Planning in Patients with Multiple Sclerosis
Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
Challenging the Status Quo in Schizophrenia Treatment
Stephen Marder, MD
Nutrition and the Gut-Brain Connection in Schizophrenia
Deanna L. Kelly, PharmD, BCPP
Minimal By Design: Define MSE Endpoints
Loading...
We're glad to see you're enjoying Global Neurology Academy… but how about a more personalized experience?
Press cancel to remain on Global Neurology Academy. Press the link below or the continue button to keep going.